Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Director Lori Anne Kunkel Sells 10,000 Shares of Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Director Lori Anne Kunkel sold 10,000 shares of Bitwise MARA Option Income Strategy ETF stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the sale, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. The trade was a 19.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lori Anne Kunkel also recently made the following trade(s):

• On Friday, June 5th, Lori Anne Kunkel sold 10,000 shares of Bitwise MARA Option Income Strategy ETF stock. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00.

Bitwise MARA Option Income Strategy ETF Price Performance

Shares of IMRA stock opened at $15.69 on Thursday. The company has a market capitalization of $2.04 million, a P/E ratio of 313.80 and a beta of 2.74. The company’s 50-day simple moving average is $16.91 and its two-hundred day simple moving average is $15.57. Bitwise MARA Option Income Strategy ETF has a one year low of $11.99 and a one year high of $54.94.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.